Bayer introduces Canesten® in India to address the under-reported fungal infections with a range of products
New Delhi – The Consumer Health division of Bayer announced the expansion of their dermatology portfolio with the introduction of a range of anti-fungal solutions in India under the name Canesten®. Available in powder and cream formats, it offers anti-fungal properties that help prevent and treat skin infections. An easy-to-use solution, Canesten® is a full-cycle skin infection control formulation that provides relief from itching and halts the spread of infection.
In order to understand the incidence of fungal infections among Indian women in the age group between 20 and 35 years, a study was initiated by Canesten® and conducted by Brand Eigen Insights And Analytics among women in Urban India across all zones during April-May 2022. Interestingly, the study found that 94% of women have suffered from at least one fungal infection in the last one year. Itching was the most common anti-fungal infection reported by 61% of women, and among these sufferers, 67% wants to address it as a top priority. Almost 50% of women used prickly heat/talcum powder as an immediate remedial solution for the infection. However, 75% of women resorted to using soap or antiseptic liquid or home remedies as a remedial solution to their anti-fungal problem.
Talking about the expansion, Sandeep Verma, Country Head, Bayer Consumer Heath India, said, “At Bayer, we are continuously working on our vision of making self-care accessible for all Indians. Women, especially those who lead a more active lifestyle, are prone to fungal skin infections in the hot-humid weather of India. Early symptom detection, diagnosis and treatment can provide relief, reduce the likelihood of recurrence, and improve their quality of life. To address this concern, we’ve brought our best global solution to India, that’s already trusted by millions of women worldwide. We want to encourage women to stop being uncomfortable and hiding fungal skin infections, rather treat them with Canesten®, and live their lives to the fullest.”
“As we focus on strengthening our dermatology portfolio in India, we are determined to take the legacy of Bayer’s original research molecule Clotrimazole to new heights and establish Canesten® as the go-to solution for skin infection in women,” he further added.
Bayer’s new range intends to bring in the required relief as it treats a wide spectrum of fungal skin infections. Canesten® anti-fungal dusting powder is used in the prevention, therapy and follow-up treatment of superficial skin fungal infections and provides 5X relief vs. ordinary talcum powder from prickly heat, redness, skin irritation, itching, and fungal infection. Canesten® cream, provides relief from ringworm, jock itch, skin candidiasis, athlete’s foot, erythrasma and fungal nail infection, among other fungal skin infections. Canesten® S cream is used for treatment of skin fungal infections with inflammatory lesions, while Canesten® V6 Tablets proves its effectiveness in the therapy of complicated vulvovaginal candidosis¹.
Available in 110 countries, a global market leader in anti-fungal solutions, the introduction of Canesten® in India highlights Bayer’s commitment to focus on bringing science-based solutions to consumers around the world, throughout all stages of life. With solutions like Canesten®,Bayer intends to address treatments of skin fungal infections amongs women, which tend to get ignored. . The communication planned by the Consumer Health division for Canesten® aims to combat the behaviour highlighted in the study by encouraging the use of an expert solution.
Canesten® dusting powder is available as 50g and 100g SKUs (Stock Keeping Units) while Canesten® cream is available in a 30g tube – all of which can be purchased as an OTC product across India. The other 2 SKUs, Canesten® S cream in 15gm tube and Canesten® V6 tablets can be purchased with a doctor’s prescription.